Cognition Therapeutics, Inc.
CGTX
Price:
$0.5949
Market Cap:
$23.88M
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, a sigma-2 receptor antagonist, which is in Phase II clinical trial for the treatment of mild-to-moderate Alzheimer's disease, as well as has completed Phase I clinical trial to treat early-stage Alzheimer's disease; in Phase II clinical trial for the treatment of dementia with Lewy bodies (DLB); and in preclinical trial to treat dry age-related macular degeneration (AMD). The company is also developing CT2168 for...[Read more]
Industry
Biotechnology
IPO Date
2021-10-08
Stock Exchange
NASDAQ
Ticker
CGTX
The ROE as of September 2024 (TTM) for Cognition Therapeutics, Inc. (CGTX) is -118.11%
According to Cognition Therapeutics, Inc.’s latest financial reports and current stock price. The company's current ROE is -118.11%. This represents a change of 297.31% compared to the average of -29.73% of the last 4 quarters.
Cognition Therapeutics, Inc. (CGTX) Historical ROE (quarterly & annually)
How has CGTX ROE performed in the past?
The mean historical ROE of Cognition Therapeutics, Inc. over the last ten years is -19.37%. The current -118.11% ROE has changed 509.58% with respect to the historical average. Over the past ten years (40 quarters), CGTX's ROE was at its highest in in the March 2020 quarter at 45.61%. The ROE was at its lowest in in the December 2023 quarter at -33.26%.
Average
-19.37%
Median
1.88%
Minimum
-105.37%
Maximum
14.77%
Cognition Therapeutics, Inc. (CGTX) ROE by Quarter and Year
Discovering the peaks and valleys of Cognition Therapeutics, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 24.12%
Maximum Annual ROE = 14.77%
Minimum Annual Increase = -5702.37%
Minimum Annual ROE = -105.37%
| Year | ROE | Change |
|---|---|---|
| 2023 | -105.37% | -5702.37% |
| 2022 | 1.88% | -109.38% |
| 2021 | -20.06% | -235.79% |
| 2020 | 14.77% | 24.12% |
Cognition Therapeutics, Inc. (CGTX) Average ROE
How has CGTX ROE performed in the past?
The current ROE of Cognition Therapeutics, Inc. (CGTX) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-41.18%
5-year avg
-19.37%
10-year avg
-19.37%
Cognition Therapeutics, Inc. (CGTX) ROE vs. Peers
How is CGTX’s ROE compared to its peers?
Cognition Therapeutics, Inc.’s ROE is less than Reviva Pharmaceuticals Holdings, Inc. (7.96%), greater than Eyenovia, Inc. (-615.55%), greater than TransCode Therapeutics, Inc. (-597.47%), greater than Kodiak Sciences Inc. (-77.23%), greater than TFF Pharmaceuticals, Inc. (-225.16%), greater than TScan Therapeutics, Inc. (-59.83%), greater than Cue Biopharma, Inc. (-142.93%), greater than Dermata Therapeutics, Inc. (-197.44%), greater than Gain Therapeutics, Inc. (-214.20%), greater than aTyr Pharma, Inc. (-56.83%), greater than IN8bio, Inc. (-173.12%), greater than Lantern Pharma Inc. (-46.39%), less than Cullinan Oncology, Inc. (0%), greater than Bolt Biotherapeutics, Inc. (-28.37%), greater than Day One Biopharmaceuticals, Inc. (-61.40%), greater than Lyra Therapeutics, Inc. (-122.70%), greater than Autolus Therapeutics plc (-143.74%), greater than null (-66.76%),
| Company | ROE | Market cap |
|---|---|---|
| 7.96% | $56.73M | |
| -615.55% | $41.36M | |
| -597.47% | $4.49M | |
| -77.23% | $138.90M | |
| -225.16% | $7.87M | |
| -59.83% | $308.31M | |
| -142.93% | $27.36M | |
| -197.44% | $2.77M | |
| -214.20% | $37.54M | |
| -56.83% | $131.12M | |
| -173.12% | $14.45M | |
| -46.39% | $41.66M | |
| 0% | $978.59M | |
| -28.37% | $24.54M | |
| -61.40% | $1.21B | |
| -122.70% | $18.33M | |
| -143.74% | $1.06B | |
| -66.76% | $0 |
Build a custom stock screener for Cognition Therapeutics, Inc. (CGTX) and other stocks
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Cognition Therapeutics, Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
Cognition Therapeutics, Inc. (CGTX) and other stocks custom spreadsheet templates
The easiest way to analyze a company like Cognition Therapeutics, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
Frequently asked questions❓
What is the ROE?
How can you use the ROE?
What is Cognition Therapeutics, Inc.'s ROE?
How is the ROE calculated for Cognition Therapeutics, Inc. (CGTX)?
What is the highest ROE for Cognition Therapeutics, Inc. (CGTX)?
What is the 3-year average ROE for Cognition Therapeutics, Inc. (CGTX)?
What is the 5-year average ROE for Cognition Therapeutics, Inc. (CGTX)?
How does the current ROE for Cognition Therapeutics, Inc. (CGTX) compare to its historical average?